Copyright
©2007 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 7, 2007; 13(41): 5465-5470
Published online Nov 7, 2007. doi: 10.3748/wjg.v13.i41.5465
Published online Nov 7, 2007. doi: 10.3748/wjg.v13.i41.5465
10 patients |
Age mean 60.20 y.o (range 35-70) |
Sex: Male/Female 7/3 |
Child-Pugh's stage: A,B/C 8/2 |
"Virus: HBsAg/anti-HCV 8/2" |
Grade of toxicity | ||||
1 | 2 | 3 | 4 | |
Oral dryness | 3 | 1 | 0 | 0 |
Diarrhea | 1 | 2 | 0 | 0 |
Vomiting | 1 | 0 | 0 | 0 |
Liver dysfunction | 1 | 2 | 0 | 0 |
Fever | 0 | 0 | 0 | 0 |
Hair loss | 1 | 0 | 0 | 0 |
BM suppression | 4 | 4 | 0 | 0 |
- Citation: Ishikawa T, Imai M, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki KI, Ohta H, Yoshida T, Kamimura T. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: A pilot study. World J Gastroenterol 2007; 13(41): 5465-5470
- URL: https://www.wjgnet.com/1007-9327/full/v13/i41/5465.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i41.5465